Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.
Groups of 122 Peruvian adults of low socioeconomic level (SEL) and 125 of high SEL received a randomly allocated 5 x 10(9)- or 5 x 10(8)-CFU dose of CVD 103-HgR live oral cholera vaccine or a placebo. The vaccine was well tolerated. Vibriocidal seroconversions occurred in 78% of high-SEL and 72% of low-SEL subjects who ingested the high dose and in 78 and 49%, respectively, of those who received the low dose.
Gotuzzo
E
E
Instituto de Medicina Tropical, Universidad Peruana Cayetano Heredia, Lima.
Butron
B
B
Seas
C
C
Penny
M
M
Ruiz
R
R
Losonsky
G
G
Lanata
C F
CF
Wasserman
S S
SS
Salazar
E
E
Kaper
J B
JB
D000284:Administration, Oral; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood*; D022121:Cholera Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D004311:Double-Blind Method; D006801:Humans; D010568:Peru; D012959:Socioeconomic Factors; D014611:Vaccination; D014734:Vibrio cholerae / Q000276:immunology*
D000907:Antibodies, Bacterial; D022121:Cholera Vaccines